What is the role of letrozole in adjuvant breast carcinoma setting?

June 2005, Volume 11, Issue 2, pp 91–91

Article

DOI: 10.1007/BF02893373

Cite this article as:: Baki, M. Pathol. Oncol. Res. (2005) 11: 91. doi:10.1007/BF02893373

1.
Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. New Engl J Med 349: 1793–1802, 2003PubMedCrossRefGoogle Scholar
2.
Wasan KM, Goss PE, Pritchard PH, et al. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years adjuvant tamoxifen (NCIC CTG MA.17L). Ann Oncol 16: 707–715, 2005PubMedCrossRefGoogle Scholar
3.
Thurlimannn B et al for the BIG I-98 Collaborative coordinated by the International Breast Cancer Study Group. Letrozole as adjuvant endocrine therapy for postmenopausal women with receptor positive breast cancer. First results of IBCSG 18-98/BIG I-98. Presented at 9th International Conference on Primary Therapy of Early Breast Cancer: January 26–29, 2005, St. Gallen, Abstr. S4

Copyright information

Get Access to

Pathology & Oncology Research

for the whole of 2017